General AML

ESH 2019 | Is AML susceptible to immunotherapy?


The AML Global Portal were delighted to speak to John DiPersio, Washington University Medical School, St. Louis, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked John DiPersio: Is AML susceptible to immunotherapy? He outlined the current challenges of  immunotherapeutic approaches in AML, such as lack of selective targets and life-threatening side-effects, and how they can potentially be overcome.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!